Effectiveness and Safety of <scp>IVIG</scp> for the Treatment of <scp>HMGCR</scp> Immune‐Mediated Necrotizing Myopathy
Patients treated with immunotherapy regimens that included IVIG were more likely to reach normal CK at 6 months. Maintenance IVIG monotherapy also induced marked improvements in CK and strength. IVIG monotherapy can be an effective first-line treatment for HMGCR IMNM.
Authors
- Joome Suh (ORCID: https://orcid.org/0000-0002-4591-1057)
- Anthony A. Amato (ORCID: https://orcid.org/0009-0006-3884-6644)
Institutions
- Brigham and Women's Hospital (US)
- Harvard University (US)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2024-12-27
- DOI
- https://doi.org/10.1002/mus.28333
- Citations
- 3
- Primary Topic
- Inflammatory Myopathies and Dermatomyositis
- Type
- article
- Field-Weighted Citation Impact
- 1.16